Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in severe refractory systemic lupus erythematosus
2023-510081-27-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of rapcabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Novartis. Primary endpoint: Safety. Started Feb 2023; status: completed.
02
Drugs
rapcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2023-510081-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510081-27-00.